Abstract
Problem: While natural products are increasingly supported by robust preclinical and clinical evidence-demonstrating significant neuroprotective, anti-inflammatory, antimicrobial, and metabolic benefits-their integration into evidence-based healthcare systems is severely hindered by inconsistent regulatory classifications and fragmented policy frameworks. Key Findings: Advances in metabolomics, systems pharmacology, standardized extraction technologies, controlled cultivation, and randomized controlled trials (RCTs) have substantially enhanced the reproducibility, safety profiles, and mechanistic understanding of natural products. Nevertheless, critical gaps persist in regulatory harmonization, clinical guideline integration, translational research funding, and professional education. Recommended Actions: Health authorities and policymakers must implement adaptive regulatory frameworks, prioritize funding for translational research, integrate validated natural products into standardized clinical guidelines, and enhance evidence-based training for healthcare professionals and regulators. Urgency: In the absence of coordinated policy reform, scientifically validated natural products will remain underutilized. This delay limits global access to potentially cost-effective therapeutic interventions and stifles innovation within healthcare systems. Target Audience: Health policymakers, regulatory authorities, healthcare administrators, clinical guideline developers, public health organizations, translational researchers, and scientific journal editors.